Medicare negotiated drug prices for 2026 and 2027
Ten drugs have had a Medicare negotiated price since January 1, 2026, and fifteen more get one on January 1, 2027, semaglutide at $274 for 30 days among them.
The Medicare Drug Price Negotiation Program, created by the Inflation Reduction Act, lets CMS set a maximum fair price for some of the brand drugs on which Part D spends the most. CMS publishes the results in a file that lists, for each drug and each package, the negotiated price for a 30-day equivalent supply and the dates it applies; the version we read is dated September 21, 2026. The first ten prices took effect on January 1, 2026, including $231 for Eliquis, $197 for Jardiance and $113 for Januvia, and most are adjusted for inflation in 2027. Fifteen more start on January 1, 2027, the largest of them semaglutide, which covers Ozempic, Rybelsus and Wegovy at $274. A third list of fifteen, including Trulicity, applies from 2028; their prices are not yet public. The negotiated price is what your Part D plan pays and the base of your coinsurance; under the standard benefit a year of Ozempic falls to about $1,347.
Medicare negotiated price of a drug
2027 price for 30 days
$274
| 2026 price for 30 days | not selected for 2026 |
| Your 2027 Part D share at this price | $1,347 |
| Selected for | 2027 |
CMS file of negotiated (maximum fair) prices; standard Part D benefit. Estimate only.
Prices read by Radif Partners · Editorial policy · Method and data
The ten drugs of 2026
| Drug | Active ingredient | 2026, 30 days | 2027, 30 days |
|---|---|---|---|
| Eliquis, Eliquis Sprinkle | apixaban | $231 | $237.25 |
| Enbrel | etanercept | $2,355 | $2,418.70 |
| Entresto, Entresto Sprinkle | valsartan / sacubitrilat | $295 | none listed |
| Farxiga | dapagliflozin | $178.50 | $183.33 |
| Imbruvica | ibrutinib | $9,319 | $9,571.07 |
| Januvia | sitagliptin | $113 | $116.06 |
| Jardiance | empagliflozin | $197 | $202.33 |
| Novolog, Novolog Flexpen, Novolog Penfill | insulin aspart, human | $119 | none listed |
| Stelara | ustekinumab | $4,695 | none listed |
| Xarelto | rivaroxaban | $197 | none listed |
4 drugs show no 2027 price (Entresto, Novolog, Stelara and Xarelto): their 2027 lines in the CMS file end before they begin. A drug leaves the program when it stops qualifying, typically when a generic or biosimilar is marketed; the plan then goes back to its own contracted price.
The fifteen drugs of 2027
| Drug | Active ingredient | 2027, 30 days |
|---|---|---|
| Austedo, Austedo Xr | deutetrabenazine | $4,093 |
| Breo Ellipta | fluticasone; vilanterol | $67 |
| Calquence | acalabrutinib | $8,600 |
| Ibrance | palbociclib | $7,871 |
| Janumet, Janumet Xr | metformin; sitagliptin | $80 |
| Linzess | linaclotide | $136 |
| Ofev | nintedanib | $6,350 |
| Otezla, Otezla Xr | apremilast | $1,650 |
| Ozempic, Rybelsus, Wegovy | semaglutide | $274 |
| Pomalyst | pomalidomide | $8,650 |
| Tradjenta | linagliptin | $78 |
| Trelegy Ellipta | fluticasone; umeclidinium; vilanterol | $175 |
| Vraylar | cariprazine | $770 |
| Xifaxan | rifaximin | $1,000 |
| Xtandi | enzalutamide | $7,004 |
The fifteen drugs selected for 2028
. CMS negotiates their prices during 2026 and publishes them once the cycle closes; the calculator will use them as soon as they appear in the file.
What a negotiated price does to your bill
The price is not a copay. It is the amount the Part D plan pays for a 30-day supply, and the base on which your 25% coinsurance is calculated after the deductible. If your plan charges a flat copay instead, the negotiated price changes the plan’s costs more than yours. It also changes how fast you reach the yearly cap: at $274 a month, a year of Ozempic adds up to $3,288, and your share under the standard benefit is about $1,347, well below the $2,400 cap. The negotiated price applies only to Medicare: it is not a cash price and pharmacies do not offer it to uninsured customers.
How a price is negotiated
CMS selects drugs with high Part D spending that have been on the market for years without generic or biosimilar competition, sends the manufacturer an initial offer, receives a counteroffer, holds negotiation meetings and publishes the agreed maximum fair price. The law sets a ceiling on that price as a share of the drug’s non-federal average manufacturer price, which is why cuts range from about half to nearly four-fifths of the 2023 list price for the first round. Participation is voluntary for manufacturers in principle, but leaving means leaving Medicare and Medicaid.
Where the GLP-1s stand
Semaglutide is the only GLP-1 with a negotiated price so far, for 2027. Dulaglutide, sold as Trulicity, is in the 2028 group. Tirzepatide (Mounjaro and Zepbound) and orforglipron (Foundayo) are not on any list; their Medicare prices stay those of each plan.